Why HeartBeam’s 510(k) appeal could reshape cardiac software approval timelines

HeartBeam, Inc. (NASDAQ: BEAT), a U.S.-based medical technology firm developing advanced diagnostic tools for cardiac care, has revealed a multi-pronged regulatory strategy following a Not Substantially Equivalent (NSE) determination issued by the United States Food and Drug Administration (FDA) regarding its 510(k) submission for its 12-lead Electrocardiogram (ECG) Synthesis Software. The unexpected response from the FDA temporarily halts HeartBeam’s push to commercialize a key component of its remote cardiac diagnostics platform but has not derailed the company’s broader vision or timeline.

According to HeartBeam, its strategy involves simultaneous regulatory pathways, including both a formal appeal and preparations for a potential resubmission. The company has indicated that recent discussions with FDA review staff have been constructive, with regulators expressing openness to engagement. While the NSE determination has created a short-term obstacle, HeartBeam emphasized that it is grounded in labeling-related concerns rather than deficiencies in the product’s performance or the clinical study supporting the application.

The decision to pursue parallel regulatory paths comes after the FDA signaled it would work with the company toward a resolution. HeartBeam’s leadership believes the concerns can be resolved without modifying the underlying technology. Instead, the focus will be on modifying labeling language to better align with FDA expectations and ensure clarity in clinical interpretation and use.

Why HeartBeam is taking a multi-path regulatory approach after the NSE ruling

The NSE ruling effectively pauses FDA clearance for HeartBeam’s ECG Synthesis Software, which is intended to convert three-dimensional ECG signals captured from a portable, cable-free device into a standard 12-lead ECG format. This technology is central to HeartBeam’s mission of bringing high-resolution cardiac diagnostics into non-hospital environments, including home settings.

Rather than appeal the decision in isolation or start from scratch, HeartBeam is opting to pursue multiple options in parallel. These include initiating the FDA’s formal appeal process, which typically concludes within approximately 60 days from the time of submission, and preparing a resubmission that could address regulatory concerns via revised documentation.

HeartBeam stated that the appeal process appears viable based on its internal analysis and initial interactions with the FDA. The company underscored that its VALID-ECG clinical study, which was submitted with the original application, met all pre-defined clinical endpoints and remains a cornerstone of its regulatory position. This study, along with HeartBeam’s previously cleared 3D ECG device for arrhythmia detection, provides a scientific foundation for the broader software platform.

The company believes its best chance of reaching a positive regulatory outcome lies in pursuing all feasible options simultaneously. This strategy allows for flexibility depending on how the FDA responds to revised materials or proposed labeling modifications.

What concerns did the FDA raise and how is HeartBeam addressing them?

According to HeartBeam, the issues flagged by the FDA relate largely to the labeling and intended use of the ECG Synthesis Software rather than its accuracy or safety. The agency appears to be seeking clearer delineation around how synthesized ECG data should be interpreted by clinicians, especially in at-home or telehealth contexts where precision and user interface clarity are critical.

Chief Executive Officer Robert Eno said HeartBeam has been engaging with the FDA in good faith for over two years, resolving most outstanding questions during that period. The current concerns, he added, are clearly defined and can be addressed through the company’s internal regulatory and clinical teams.

The company plans to revise the labeling language to ensure alignment with FDA expectations. This likely includes clarifying how clinicians should interpret synthesized ECG outputs, how the software integrates with broader diagnostic workflows, and how it differs from traditional wired ECG systems used in clinical settings.

Labeling changes are generally viewed by industry observers as a more favorable scenario than performance-based rejection, as they typically do not require product redesign or new trials. If the FDA agrees with HeartBeam’s revised labeling, clearance could be achieved relatively quickly under the existing submission or via the appeal route.

How does this affect HeartBeam’s commercial launch and funding roadmap?

Despite the regulatory pause, HeartBeam reiterated that it is continuing with preparations for its commercial launch and funding roadmap. The company intends to keep shareholders informed of all developments as it works through the FDA process.

While a delay in clearance may have near-term implications for commercial rollout and revenue generation, HeartBeam’s broader strategy remains intact. The firm has already received FDA clearance for a related device that uses 3D ECG to assess arrhythmias and believes its patent portfolio and platform differentiation remain strong.

The potential resolution timeline tied to the appeal process suggests a decision could be reached within the first quarter of 2026. If that happens, HeartBeam may still be able to initiate commercialization of the ECG Synthesis Software in the first half of the year. This timeline could preserve investor confidence and allow the firm to maintain momentum across strategic, funding, and operational fronts.

HeartBeam’s commercial aspirations include embedding its 3D ECG technology into portable, cable-free devices that can be used outside of hospital settings. By synthesizing full 12-lead ECG readings from three non-coplanar vectors, the technology enables remote triage, early detection of acute cardiac conditions, and trend monitoring across a range of cardiovascular health issues.

What sets HeartBeam’s ECG platform apart from other cardiac technologies?

HeartBeam is attempting to redefine the way cardiac diagnostics are delivered by developing a device that collects ECG signals in 3D from five electrodes placed on the body, then synthesizes those signals into a standard 12-lead ECG format. This capability is designed for remote or at-home environments, providing clinicians with actionable data without requiring patients to visit a hospital or clinic.

In December 2024, HeartBeam received FDA clearance for its arrhythmia-focused ECG platform, which validated the company’s approach to remote diagnostics. The current software application builds on that foundation by aiming to offer a more complete picture of cardiac activity through synthesized 12-lead ECGs.

The firm currently holds over 20 issued patents and has indicated that its intellectual property pipeline spans both hardware and software. Its longer-term vision includes seamless integration with physician-facing software viewers and potential use in telehealth environments where quick, accurate cardiac data can help guide treatment decisions or referrals to emergency care.

While the NSE ruling delays immediate commercialization, it does not impact the previously cleared device or invalidate HeartBeam’s underlying scientific claims. If the firm succeeds in obtaining clearance for its software, it could become one of the first to deliver cable-free 12-lead ECG synthesis from a consumer-scale device.

What is the outlook for HeartBeam and what are investors watching next?

Investor sentiment surrounding HeartBeam, Inc. remains cautiously optimistic. Shares of the company (NASDAQ: BEAT) have experienced modest volatility following the announcement, though many institutional watchers believe the firm’s proactive regulatory approach and prior FDA clearance provide reason for confidence.

Analysts familiar with the situation noted that the nature of the FDA’s concerns, limited primarily to labeling rather than clinical efficacy or safety, suggests a manageable path forward. The appeal process provides a defined timeline and clear procedural benchmarks, while the option to resubmit preserves flexibility if needed.

Short-term investor focus will likely revolve around the timing and outcome of the appeal. Should the FDA accept revised labeling and move toward clearance within the 60-day window, HeartBeam could regain momentum and possibly revisit prior commercial guidance.

Longer-term, the company’s success will hinge on its ability to expand adoption of its remote cardiac diagnostic platform, enter strategic partnerships, and secure reimbursement pathways for its technology. If successful, HeartBeam could emerge as a key player in the broader shift toward decentralized cardiac care.

The company has confirmed it will continue to provide regular updates to shareholders and regulatory stakeholders as the FDA process unfolds.

What are the key takeaways from HeartBeam’s response to the FDA’s NSE decision?

• HeartBeam, Inc. received a Not Substantially Equivalent (NSE) determination from the United States Food and Drug Administration on its 510(k) application for 12-lead ECG Synthesis Software.

• The regulatory setback is centered around labeling concerns rather than issues related to clinical performance or device safety.

• The company’s VALID-ECG clinical study met all agreed-upon endpoints, supporting the validity of the software’s functionality.

• HeartBeam is pursuing multiple regulatory strategies in parallel, including a formal appeal process expected to take approximately 60 days and a potential resubmission of the 510(k) application.

• The FDA has shown willingness to engage with HeartBeam and work toward a constructive resolution.

• CEO Robert Eno emphasized that most technical questions have been resolved through a two-year engagement with the FDA and that remaining concerns are clearly defined and addressable.

• The company believes revised labeling language will satisfy the FDA’s requirements without altering the software’s core technology.

• HeartBeam will continue to update shareholders while moving forward with its commercial launch and funding roadmap despite the regulatory delay.

• The company previously received FDA clearance for a 3D ECG-based device in December 2024 and holds more than 20 issued patents in cardiac diagnostics.

• Investor sentiment remains cautiously positive, with analysts noting that the nature of the FDA’s concerns does not appear to threaten HeartBeam’s long-term market opportunity.